구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state | ||
|---|---|---|---|
Overview Program | Tecvayli (teclistamab) | Elranatamab | Blinatumomab |
Overview Company | Johnson & Johnson | Pfizer | Amgen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | BCMA × CD3 | FRα | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | Relapsed or refractory multiple myeloma | Multiple Myeloma | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and du | novel mechanisms of action that traditional monoclonal antibodies cannot achieve |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | resistance to available treatments | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
Positioning Development positioning | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. | — | — |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | targeting both B-cell maturation antigen | targeting CD19/20/22 and engineered chimeric antigen receptor |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. | BCMA-targeted therapies and feasibility in selected high | CD19 expression, whereas cytoplasmic CD22 expression |
PK/PD Half-life | ~2–3 weeks at steady state | — | — |
PK/PD Species | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA | Mouse, Human | Mouse |
PK/PD Animal (cat.) | Human, NHP | Human, Mouse | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | pharmacokinetic |
Toxicology Species | Mouse | Mouse, Human | Mouse |
Toxicology Animal (cat.) | — | Unknown | Mouse, In vitro |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% | 58% | 1% |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Clinical Selected reported efficacy | ORR 63% | ORR 61% | 10% |
Clinical Reported ORR | 63.0% | 56.0% | — |
Clinical Reported PFS | ~11.3 mo | — | NA |
Clinical Reported OS | — | — | NA |
Clinical Result source | MajesTEC-1 (NCT03145181 / NCT04557098) | ClinicalTrials.gov NCT05565391 | ClinicalTrials.gov NCT03298412 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03145181 | NCT05565391 | NCT03298412 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state | ||
|---|---|---|---|
Overview Program | Tecvayli (teclistamab) | Elranatamab | Blinatumomab |
Overview Company | Johnson & Johnson | Pfizer | Amgen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | BCMA × CD3 | FRα | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | Relapsed or refractory multiple myeloma | Multiple Myeloma | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and du | novel mechanisms of action that traditional monoclonal antibodies cannot achieve |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | resistance to available treatments | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
Positioning Development positioning | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. | — | — |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | targeting both B-cell maturation antigen | targeting CD19/20/22 and engineered chimeric antigen receptor |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. | BCMA-targeted therapies and feasibility in selected high | CD19 expression, whereas cytoplasmic CD22 expression |
PK/PD Half-life | ~2–3 weeks at steady state | — | — |
PK/PD Species | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA | Mouse, Human | Mouse |
PK/PD Animal (cat.) | Human, NHP | Human, Mouse | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | pharmacokinetic |
Toxicology Species | Mouse | Mouse, Human | Mouse |
Toxicology Animal (cat.) | — | Unknown | Mouse, In vitro |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% | 58% | 1% |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Clinical Selected reported efficacy | ORR 63% | ORR 61% | 10% |
Clinical Reported ORR | 63.0% | 56.0% | — |
Clinical Reported PFS | ~11.3 mo | — | NA |
Clinical Reported OS | — | — | NA |
Clinical Result source | MajesTEC-1 (NCT03145181 / NCT04557098) | ClinicalTrials.gov NCT05565391 | ClinicalTrials.gov NCT03298412 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03145181 | NCT05565391 | NCT03298412 |
추천 비교
추천 비교